Paradigm Biopharmaceuticals (PAR AU)

Analysis

Health Care • Australia

Paradigm Biopharmaceuticals Limited operates as a biopharmaceutical company. The Company develops PPS drug to treat respiratory diseases such as allergic asthma, allergic rhinitis, and chronic obstructive pulmonary. Paradigm Biopharmaceuticals offers its services in Australia.

Refresh

Focused

No publications yet

Add Paradigm Biopharmaceuticals to your Watchlist to get alerts on new publications

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00